Synairgen’s Hopes For Inhaled COVID-19 Therapy Dwindle
Hospital Study Fails
The company is running out of chances for its inhaled interferon therapy after a Phase III study failed to show benefits for hospitalized COVID-19 patients.
You may also be interested in...
SNG001 has moved into a Phase III open label trial in which it must prove its non-inferiority against Regeneron's monoclonal antibody cocktail.
Beam is the latest allogeneic CAR-T developer to face a regulatory hold-up, but other candidates using its pioneering base-editing technology are now progressing.
AstraZeneca’s momentum is growing towards ‘industry-leading' revenue growth, but investors are focused on the operating margin, and concerned about when CEO Pascal Soriot will depart.